Mouse Model of Alcoholic Steatohepatitis.
Sign Up to like & getrecommendations! Published in 2020 at "Methods in molecular biology"
DOI: 10.1007/978-1-0716-0704-6_15
Abstract: Alcoholic liver disease (ALD) is one of the most common causes of chronic liver disease in Western countries. The spectrum of ALD ranges from simple steatosis to steatohepatitis to cirrhosis and hepatocellular carcinoma. Over the… read more here.
Keywords: alcoholic steatohepatitis; model; steatohepatitis; binge ... See more keywords
Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitis.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular and cellular biochemistry"
DOI: 10.1007/s11010-022-04430-3
Abstract: Non-alcoholic steatohepatitis (NASH) is a rapidly growing liver disease. The chemoattractant chemerin is abundant in hepatocytes, and hepatocyte expressed prochemerin protected from NASH. Prochemerin is inactive and different active isoforms have been described. Here, the… read more here.
Keywords: hepatocyte expressed; chemerin; alcoholic steatohepatitis; non alcoholic ... See more keywords
Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine"
DOI: 10.1007/s12020-021-02716-y
Abstract: Our study aimed to uncover the crucial genes and functional pathways involved in the development of non-alcoholic steatohepatitis (NASH). Liver transcriptome datasets were integrated with Robust rank aggregation (RRA) method, and transcriptomic signatures for NASH… read more here.
Keywords: fibrosis; non alcoholic; alcoholic steatohepatitis; transcriptomic signatures ... See more keywords
Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model.
Sign Up to like & getrecommendations! Published in 2020 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2020.119823
Abstract: Non-alcoholic steatohepatitis (NASH) is associated with liver fibrosis and cirrhosis, which eventually leads to hepatocellular carcinoma. Although several animal models were developed to understand the mechanisms of NASH pathogenesis and progression, it remains obscure. A… read more here.
Keywords: non alcoholic; alcoholic steatohepatitis; liver; steatohepatitis nash ... See more keywords
Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Chemico-biological interactions"
DOI: 10.1016/j.cbi.2020.109054
Abstract: BACKGROUND AND AIMS Non-alcoholic steatohepatitis (NASH) has been associated with fibrosis that may progress to cirrhosis. The purpose of this study was to examine hepatocytes and perisinusoidal cells in liver biopsies of 3 families (3… read more here.
Keywords: non alcoholic; alcoholic steatohepatitis; liver biopsies; nash ... See more keywords
The mechanism by which ATP regulates alcoholic steatohepatitis through P2X4 and CD39.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2021.174729
Abstract: Alcoholic liver disease caused by chronic excessive drinking has become one of the most common types of liver disease. Alcohol-induced inflammatory immune responses play a central role in the development of alcohol-associated steatohepatitis. The content… read more here.
Keywords: expression; cd39; p2x4; atp ... See more keywords
Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity.
Sign Up to like & getrecommendations! Published in 2022 at "Endocrinologia, diabetes y nutricion"
DOI: 10.1016/j.endien.2022.02.017
Abstract: BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in morbid obesity (MO). A considerable proportion of patients with MO have non-alcoholic steatohepatitis (NASH). Liver biopsy (LB) is the only procedure that reliably differentiates NASH… read more here.
Keywords: prevalence predictors; alcoholic steatohepatitis; morbid obesity; non alcoholic ... See more keywords
CD44 is a key player in non-alcoholic steatohepatitis.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2017.03.003
Abstract: BACKGROUND & AIMS Cluster of differentiation (CD)44 regulates adipose tissue inflammation in obesity and hepatic leukocyte recruitment in a lithogenic context. However, its role in hepatic inflammation in a mouse model of steatohepatitis and its… read more here.
Keywords: key player; non alcoholic; inflammation; alcoholic steatohepatitis ... See more keywords
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2018.09.024
Abstract: BACKGROUND & AIMS Non-invasive tools for monitoring treatment response and disease progression in non-alcoholic steatohepatitis (NASH) are needed. Our objective was to evaluate the utility of magnetic resonance (MR)-based hepatic imaging measures for the assessment… read more here.
Keywords: non alcoholic; histology; alcoholic steatohepatitis; liver ... See more keywords
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2018.11.032
Abstract: BACKGROUND NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes the rate-limiting… read more here.
Keywords: patients nash; non alcoholic; rosuvastatin; cholesterol ... See more keywords
Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Sign Up to like & getrecommendations! Published in 2019 at "Life sciences"
DOI: 10.1016/j.lfs.2019.05.014
Abstract: AIMS In addition to potentially progressing to either cirrhosis or hepatocellular carcinoma, non-alcoholic steatohepatitis (NASH) is currently the leading indication for liver transplantation. Nintedanib has been clinically used to treat idiopathic pulmonary fibrosis for many… read more here.
Keywords: fibrosis; histological evaluation; non alcoholic; alcoholic steatohepatitis ... See more keywords